Compare DCO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | TPST |
|---|---|---|
| Founded | 1849 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 11.3M |
| IPO Year | N/A | N/A |
| Metric | DCO | TPST |
|---|---|---|
| Price | $122.45 | $2.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $128.40 | $10.00 |
| AVG Volume (30 Days) | ★ 157.6K | 90.9K |
| Earning Date | 02-26-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $806,224,000.00 | N/A |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.17 | N/A |
| 52 Week Low | $51.76 | $2.16 |
| 52 Week High | $124.50 | $12.37 |
| Indicator | DCO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 67.97 | 35.01 |
| Support Level | $119.84 | $2.16 |
| Resistance Level | $124.50 | $2.46 |
| Average True Range (ATR) | 4.12 | 0.22 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 77.02 | 11.90 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.